Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
clinical trial
daratumumab
hemodialysis
multiple myeloma
relapsed/refractory
renal impairment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Sep 2023
21 Sep 2023
Historique:
received:
10
08
2023
revised:
11
09
2023
accepted:
18
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as these patients are frequently excluded from clinical trials. This investigator-initiated multicentric phase II GMMG-DANTE trial evaluated daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory (r/r) MM patients with severe RI. r/rMM patients with ≥1 prior treatment line and a GFR <30 mL/min/1.73 m
Identifiants
pubmed: 37760637
pii: cancers15184667
doi: 10.3390/cancers15184667
pmc: PMC10526417
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Janssen (Germany)
ID : n/a
Références
Nephrol Dial Transplant. 2010 Apr;25(4):1200-6
pubmed: 20037169
Clin Chem. 2007 Apr;53(4):766-72
pubmed: 17332152
Am J Hematol. 2023 Sep;98(9):E226-E229
pubmed: 37340832
Leukemia. 2021 Feb;35(2):562-572
pubmed: 32444867
Haematologica. 2022 Jun 01;107(6):1397-1409
pubmed: 34647444
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Cancers (Basel). 2021 Oct 09;13(20):
pubmed: 34680184
PLoS One. 2014 Jul 08;9(7):e101819
pubmed: 25003848
J Clin Oncol. 2018 Jul 10;36(20):2035-2043
pubmed: 29394124
Leukemia. 2013 Feb;27(2):423-9
pubmed: 22763386
Blood Cancer J. 2022 Nov 29;12(11):162
pubmed: 36446771
Nat Rev Nephrol. 2012 Feb 21;8(4):234-43
pubmed: 22349488
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood. 2016 Jul 7;128(1):37-44
pubmed: 27216216
Blood. 2003 Nov 15;102(10):3759-64
pubmed: 12881316
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Lancet Oncol. 2023 Jul;24(7):e293-e311
pubmed: 37414019
Leuk Lymphoma. 2021 Jun;62(6):1386-1395
pubmed: 33416412
Lancet. 2019 Dec 7;394(10214):2096-2107
pubmed: 31735560
J Clin Oncol. 2016 May 1;34(13):1544-57
pubmed: 26976420
Haematologica. 2018 Dec;103(12):2088-2096
pubmed: 30237262
Ann Oncol. 2014 Jan;25(1):195-200
pubmed: 24356630
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484